Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention
Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention
复制标题
DOI：
10.1002/mc.22645
复制
发表时间：
2017-08
影响因子：
4.6
通讯作者：
Ning Zheng;Jiahang Chen;Tao Li;Weiqun Liu;Jian Liu;Hongning Chen;Jichuang Wang;L. Jia
中科院分区：
文献类型：
--
作者：
Ning Zheng;Jiahang Chen;Tao Li;Weiqun Liu;Jian Liu;Hongning Chen;Jichuang Wang;L. Jia
最近的全球流行病学研究显示，长期使用口服避孕药可降低卵巢癌死亡率。然而，根本的作用机制尚不清楚。在这里，我们使用流产剂metapristone（RU 486衍生物）来测试避孕药可能中断CXCL 12/CXCR 4趋化因子轴以抑制卵巢癌转移的假设。浓度为0.000000 mg/L的美他司酮（
Recent global epidemiological studies revealed the lower ovarian cancer death from long‐term use of oral contraceptives. However, the underlying mechanism of action is not clear. Here, we use the abortifacient metapristone (RU486 derivative) to test the hypothesis that the contraceptives might interrupt CXCL12/CXCR4 chemokine axis to inhibit ovarian cancer metastasis. Metapristone at concentrations (